

FIRST TIME GENERIC APPROVAL

Brand Name	insulin glargine
Generic Name	insulin glargine
Drug Manufacturer	Winthrop U.S.

New Drug Approval

TYPE OF CLINICAL UPDATE

First Time Generic

FDA APPROVAL DATE

January 2021

LAUNCH DATE

May 2, 2022

REVIEW DESIGNATION

N/A

TYPE OF REVIEW

Biologic License Application (BLA): 021081

DISPENSING RESTRICTIONS

N/A

Overview

INDICATION FOR USE

Insulin glargine is a long-acting human insulin analog indicated to improve glycemic control in adults and pediatric patients with type 1 diabetes mellitus and in adults with type 2 diabetes mellitus.

MECHANISMS OF ACTION

The primary activity of insulin, including insulin glargine, is regulation of glucose metabolism. Insulin and its analogs lower blood glucose by stimulating peripheral glucose uptake, especially by skeletal muscle and fat, and by inhibiting hepatic glucose production. Insulin inhibits lipolysis and proteolysis and enhances protein synthesis.

DOSE FORM AND STRENGTH

Injection: 100 units/mL (U-100) available as:

- 10 mL multiple-dose vial
- 3 mL single-patient-use SoloStar prefilled pen.

DOSE & ADMINISTRATION

- Individualize dosage based on metabolic needs, blood glucose monitoring, glycemic control, type of diabetes, and prior insulin use.

This document is designed to be an informational resource to facilitate discussion and should be used neither as a basis for clinical decision-making or treatment nor as a substitute for reading original literature. RxAdvance makes every effort to ensure that the information provided is up-to-date, accurate, and complete, but no guarantee is made to that effect. If this information is provided to clients or vendors, it is subject to any contractual confidentiality provisions. Third-party disclosures are in violation of confidentiality provisions.

FIRST TIME GENERIC APPROVAL

- Administer subcutaneously into the abdominal area, thigh, or deltoid once daily at any time of day, but at the same time every day.
- Do not dilute or mix with any other insulin or solution.
- Rotate injection sites to reduce risk of lipodystrophy and localized cutaneous amyloidosis.
- Closely monitor glucose when changing to Insulin glargine and during initial weeks thereafter.

This document is designed to be an informational resource to facilitate discussion and should be used neither as a basis for clinical decision-making or treatment nor as a substitute for reading original literature. RxAdvance makes every effort to ensure that the information provided is up-to-date, accurate, and complete, but no guarantee is made to that effect. If this information is provided to clients or vendors, it is subject to any contractual confidentiality provisions. Third-party disclosures are in violation of confidentiality provisions.